Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25448023 | 0.86 | MAPT (0.50) | ALDH1A1POLBKMT2AMEN1KDM4E | |
| SCHEMBL9494042 | 0.79 | LMNA (0.50) | ALDH1A1POLBKMT2AMEN1KDM4E | |
| SCHEMBL3553416 | 0.78 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1MAPTCYP1A2 | |
| SCHEMBL13381412 | 0.70 | HDAC3 (0.60) | ALDH1A1POLBKMT2AMEN1HPGD | |
| SCHEMBL17682674 | 0.70 | POLB (0.45) | ALDH1A1POLBKMT2AMEN1KDM4E | |
| SCHEMBL8877167 | 0.69 | FABP4 (0.66) | ALDH1A1POLBKMT2AMEN1MAPT | |
| SCHEMBL2710816 | 0.69 | KMT2A (0.53) | ALDH1A1POLBKMT2AMEN1LMNA | |
| SCHEMBL6079845 | 0.69 | MEN1 (0.43) | ALDH1A1KMT2AMEN1MAPTCYP1A2 | |
| SCHEMBL1424790 | 0.69 | ALOX15 (0.48) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL19678528 | 0.68 | TPMT (0.43) | ALDH1A1POLBKMT2AMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144142-A1 | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | McSAF Inside Oncology (FR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144142-A1 | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | CD47, NCL, EPCAM | ALDH1A1 1256/4885POLB 2596/4885KMT2A 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.